Abstract: Objective To analyze the efficacy and safety of transarterial chemoembolization (TACE) combined with anti-angiogenic drugs and programmed death receptor-1 (PD-1) inhibitors in the treatment of intermediate/advanced hepatocellular carcinoma (HCC).Methods Patients treated with TACE + anti-angiogenic drugs + PD-1 inhibitors who were hospitalized in Department of Gastroenterology in Xijing hospital from June 2018 to October 2020 were enrolled. The basic clinical characteristics, objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and related adverse reactions (AEs) of the patients were collected to explore the efficacy and safety of combined treatment.Results A total of 35 patients were enrolled. At the end of follow-up, 17 patients (48.6%) had died and 18 patients (51.4%) were still alive. The median PFS was 8.9 months (95%CI: 6.3-11.6) and the median OS was 16.1 months (95%CI: 11.4-20.9). The overall ORR was 60.0% and the disease control rate (DCR) was 85.7%. Among the 35 patients who received treatment, 9 patients (25.7%) had adverse reactions (AEs) above grade two. The adverse reactions improved after reducing the dosage and/or receiving symptomatic treatment.Conclusion Combination therapy has a certain therapeutic effect on patients with intermediate/advanced HCC, and the adverse reactions are relatively controllable.    

Key words: Hepatocellular carcinoma, Transarterial chemoembolization, PD-1 inhibitors, Retrospective study